Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 20, 2019
Daily News
December 20, 2019
- Japan to Shave Drug Spending by 4.38% in FY2020 Price Revision: MHLW
December 20, 2019
- Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
- MHLW Council Holds Off Nonprescription Switches for Domperidone, Menatetrenone
December 20, 2019
- Daiichi Sankyo/Amgen’s Avastin Biosimilar Now Available
December 20, 2019
- Astellas/Seattle Genetics Nabs FDA OK for 1st-in-Class ADC
December 20, 2019
- Takahiko Iwaya to Take Over as Sanofi Japan President on Jan. 1
December 20, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…